Compare PLX & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLX | OXSQ |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.4M | 137.5M |
| IPO Year | 1996 | N/A |
| Metric | PLX | OXSQ |
|---|---|---|
| Price | $2.43 | $1.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 649.1K | ★ 1.5M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 22.83% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | $3.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $1.05 |
| 52 Week High | $3.19 | $2.42 |
| Indicator | PLX | OXSQ |
|---|---|---|
| Relative Strength Index (RSI) | 69.03 | 62.18 |
| Support Level | $2.06 | $1.20 |
| Resistance Level | $2.66 | $1.95 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 98.36 | 97.01 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.